EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY-NC 4.0

Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer’s Disease: A Systematic Review

Yulin Liang, Vincent Doré, Christopher C Rowe, Natasha Krishnadas

Journal of Alzheimer's Disease Reports · 09.01.2024 · 8 (1) · 777-789

DOI: 10.3233/adr-230181 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Journal of Alzheimer's Disease Reports, online erschienen am 07.05.2024. Verfasst von Yulin Liang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Alzheimer’s disease (AD) is the most common cause of dementia. While preclinical studies have shown benefits of glucagon-like peptide 1 receptor agonists (GLP-1 RA) in targeting core AD pathology, clinical studies are limited.

Objective

A systematic review was performed to evaluate GLP-1 RAs in AD for their potential to target core AD pathology and improve cognition.

Methods

Searches were conducted via three different databases (PubMed, Embase, and Cochrane Library). Search terms included Medical Subject Headings (MeSH) terms: ‘glucagon-like peptide 1 receptor agonist’ and ‘Alzheimer’s disease’, as well as entry terms ‘GLP-1 RA’, ‘AD’, and three types of GLP-1 RA: ‘liraglutide’, ‘exenatide’, and ‘lixisenatide’.

Results

A total of 1,444 studies were screened. Six articles that met criteria were included (four randomized control trials [RCTs] and two protocol studies). Two RCTs with amyloid-β and tau biomarker endpoints did not observe an end of treatment difference between the placebo and treated groups. In three RCTs with cognitive endpoints, there was no end of treatment difference between placebo and treated groups. GLP-1 RA showed metabolic benefits, such as lower body mass index and improved glucose levels on oral glucose tolerance tests in treated groups. GLP-1 RA may mitigate the decline in cerebral glucose metabolism and show enhanced blood-brain glucose transport capacity using 18 F-FDG PET, however, more data is needed.

Conclusions

GLP-1 RA therapy did not alter amyloid-β and tau biomarkers nor show improvements in cognition but showed potential metabolic and neuroprotective benefits.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer’s diseaseamyloidcognitionglucagon-like peptide 1tau protein

Autor:innen und Institutionen

  • Faculty of Medicine, Dentistry, and Health Sciences, The University of Melbourne, Melbourne, VIC, Australia.
  • Health and Biosecurity Flagship, The Australian e-Health Research Centre, Melbourne, VIC, Australia.
  • Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia.
  • Florey Department of Neuroscience and Mental Health, The University of Melbourne, Heidelberg, VIC, Australia.
  • Florey Institute of Neuroscience and Mental Health, Heidelberg, VIC, Australia.

Zitieren

APA

Liang, Y., Doré, V., Rowe, C. C., & Krishnadas, N. (2024). Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer’s Disease: A Systematic Review. Journal of Alzheimer's Disease Reports, 8(1), 777-789. https://doi.org/10.3233/adr-230181

Vancouver

Liang Y, Doré V, Rowe CC, Krishnadas N. Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer’s Disease: A Systematic Review. Journal of Alzheimer's Disease Reports. 2024;8(1):777-789. doi:10.3233/adr-230181

BibTeX
@article{Liang2024,
  author = {Liang, Yulin and Doré, Vincent and Rowe, Christopher C and Krishnadas, Natasha},
  title = {Clinical Evidence for GLP-1 Receptor Agonists in Alzheimer’s Disease: A Systematic Review},
  journal = {Journal of Alzheimer's Disease Reports},
  year = {2024},
  volume = {8},
  number = {1},
  pages = {777--789},
  doi = {10.3233/adr-230181}
}
Kostenlos starten →